Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.

Jéssica Barreto Ribeiro Dos Santos Rosângela Maria Gomes Michael Ruberson Ribeiro da Silva

Published in: Expert review of clinical immunology (2022)

Efgartigimod was efficacious and safe for generalized myasthenia patients with AChR antibody-positive patients. These findings need to be confirmed in AChR antibody-negative patients, and long-term safety studies are currently ongoing.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
emergency department
myasthenia gravis
adverse drug